BCL2 and triple-negative breast carcinoma: Our analysis dealt with a double-edged sword with the BH4 domain as a novel site for the targeted inhibition of BCL-2, on one side, and triple-negative breast cancer on the other side, and proposed covalent modification as a plausible solution for tackling these two challenges.